3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
12
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
27
Neoplasm Metastasis
5
Advanced Solid Tumors
5
Stomach Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Advanced Solid Tumors (Excluding Breast Cancer)
2
Urologic Diseases
1
Spinocerebellar Degenerations
1
Solid Tumor Cancer
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Renal Insufficiency
1
Refractory Solid Tumors
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Lung Neoplasms
1
Liver Neoplasms
1
Liver Diseases
1
Kidney Neoplasms
1
Kidney Diseases
1
Head and Neck Neoplasms
1
HER2 IHC3+ Advanced Colorectal Cancer
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Desmoid Tumors
1
Interventions
Fluorouracil
21
Oxaliplatin
17
Leucovorin
17
Bevacizumab
17
Irinotecan
13
Panitumumab
12
Cetuximab
12
IFL protocol
9
Capecitabine
9
pembrolizumab
7
Radiotherapy
7
Pemetrexed
5
Gemcitabine
5
labetuzumab
3
conatumumab
3
Cisplatin
3
Carboplatin
3
Albumin-Bound Paclitaxel
3
5,11-methenyltetrahydrohomofolate
3
130-nm albumin-bound paclitaxel
3
vatalanib
2
trametinib
2
spartalizumab
2
pegfilgrastim
2
ganitumab
2
encorafenib
2
dostarlimab
2
Ramucirumab
2
Paclitaxel
2
Melphalan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Rectal Neoplasms
×
trifluridine tipiracil drug combination
×
Clear all
NCT06607458
2026-06-01
DEL-LIVER
Delcath Systems Inc.
Phase 2
Recruiting
90 enrolled